The occurrence of liver metastases is a common development from a number of different forms of malignancy but is especially prevalent in patients first diagnosed with primary colorectal cancer. Hepatic metastases are evident in approximately a quarter of patients at initial diagnosis, but this is more than doubled at the time of death (Bengmark and Hafstrom, 1969) . Approximately 70% of the metastases attributed to tumours of the large bowel are fdund in the liver, and half the deaths from bowel cancer result from disease in the liver (Gray, 1980) .
Over the past two decades there have been many randomised clinical trials that have assessed the potential of adjuvant chemotherapy and radiotherapy to improve survival in patients undergoing resection for primary tumours of the large bowel. The past 3 years has seen a resurgence of interest in this area as several of these trials have now demonstrated positive results (Gray et al., 1987; Laurue et al., 1989; Moertel et al., 1990) .
Of particular interest is the fact that three of the prospectively randomised trials have demonstrated an improvement in survival with the use of regional perfusion chemotherapy of the liver as an adjuvant treatment (Taylor et al., 1985; Gray et al., 1987; Wolmark et al., 1990) . In all three of these clinical trials a relatively small dose of chemotherapy was delivered directly into the portal venous circulation following removal of the primary tumour in patients who had either stage B or C large bowel cancer. These data indicate that elimination or suppression of micrometastases within the liver in patients at high risk of developing clinically obvious recurrent cancer can translate into a survival improvement when the chemotherapy is given directly into the portal venous circulation.
In earlier studies we have shown that even very small subclinical metastases derive their blood supply almost entirely from the hepatic artery and that metastases as small as 1 mm in diameter have a well-defined arterial blood supply and that this arterial supply will occur in a short period of time (Archer and Gray. 1989 (Archer and Gray, 1990) . This effect may be associated with the low tissue penetration of the chemotherapy drugs, which are unable to diffuse from the portal veins to the arterial feeding vessels of the larger deposits.
As would be expected, many studies have established that the objective response rate for treatment of liver metastases is considerably higher when the chemotherapy is delivered directly into the hepatic arterial circulation, as opposed to systemic therapy (Daly et al., 1987; Archer and Gray, 1990) . SIR therapy is a technique developed by our group for selectively concentrating radioactive microspheres containing yttrium-90 into the vascular compartment of malignant tumours within the liver Gray et al.. 1989 Gray et al.. , 1992 . In patients with liver metastases derived from the large bowel, the objective response rate of established metastases to treatment by SIR therapy exceeds that of other treatment techniques, including hepatic perfusion chemotherapy (Gray et al., 1992 The current study was designed to evaluate the potential of using a relatively small and a high intrhepatic radiation dose delivered on radioactive microspheres via the portal vein to retard the growth of micrometastases in an animal model of liver metastasis.
MateriaL ad in&od
Twnour model A total of 15 mixed sex Wistar rats with mean body weight of 290.0 g (45.9 g s.d.) were randomly assigned to three equal groups for the purposes of the study. The tumour cell line used was derived from DMH-induced colonic carcinomas and was delivered on tumour spheroids usng the method of Archer and Gray (1988) . Briefly, the model entails harvesting tumour cells which adhere in a monolayer to ion exchange spheroids of 32-45 pm diameter. The spheroids with their load of tumour cells can then be injected into the portal vein, where they travel into the liver and embolise portal vessels. Tumour deposits will then grow at the site of embolisation and do not move into the venous system, thus confining the seeded tumour to the liver. Growth rates and a detailed methodology have been described previously (Archer and Gray, 1988) .
Radioactive microspheres
The radioactive microspheres used in the study were closely sized resin-based particles of 32.5 ± 2.5 sum diameter containing the highly energetic isotope yttrium-90. The isotope is a pure beta emitter with a half life of 64 h, a maximum range in tissue of 11 mm and a mean range of 4.5 mm (KIemp et al., 1989) . The microspheres have a specific gravity of <2.0 and have been shown not to leach activity in vio, and the partcles distribute evenly throughout the liver when delivered intravascularly. The micrres are stable and cause minimal tisse reaction even after being in the lver for extensive periods . The activity of the microspheres was approximately 65 Bq per sphere and a stock suspension was dispensed at a concentration of 50 MBq per ml of disilled water.
The radiation dose to liver tissue was based initially on an estimated average liver weight of 15 g for each animal treated. Absorbed dose for tissue was caculated as 1.82 Gy for every 37 MBq per kg of liver (Mantravadi et al., 1982) . The calculation was thus derived from the following equation:
The calculation however, is based on homogeneous distribution of dose throughout the tissue substance. This is not the case with point sourced radiation as provided on microspheres distributed primarily in the tumour and hver vasculature. There will be areas of extremely high dose near the microspheres and of low dose away from them. The mean doses described in the calculation are thus overstated by a constant fraction related to the tissue volume not riving the maximum doses and doses are therefore designated as 'inferred' doses. This concept has been described in detail previously (Fox et al., 1991) (Figure 1 ).
At the time of sacrifice there was no obvious damag to the liver of treated animas that could be associatd with the radioactive m. The hvers of the animals treated with the non-radioactive mcopes demstaed extene signs of tumour deposition but otherwise there was no damage to the normal liver parechyma. One animal in the 10 MBq group had a small number of tumour deposits sit- 
20 Mbq (total of eight tumours weighig 0.57g) The small deposits of tumour that did grow in three of the ten animals treated with radiation probably resulted from slight inhomogeneity of distribution of the microspheres from lobe to lobe. This may lead to areas of liver that are insufficiently irradiated to suppress the metastases and is a common occurrence in the multilobulate liver of the rat. Studies from this laboratory using sheep liver as an organ model (Burton et al.. 1988) have shown that this does not occur to the same extent where the liver is bilobular as in the human and distribution is relatively homogeneous. We have also experienced severe inhomogeneity when ceramic microspheres are used rather than the SIR spheres. This is attributed to the high specific density of ceramic microspheres, causing sedimentation in the vasculature. and thus making them unsuitable for clinical use.
The post-treatment liver function tests demonstrate abnormalities of liver enzyme function that are consistent with some damage to the normal liver parenchyma. However, these tests were performed on the 19th day following treatment and do not reflect alterations to long-term function of the liver that has been subjected to irradiation by yttrium-90. In patients with established liver metastases we have shown that it is possible to deliver inferred liver radiation doses of the order of 74 Gy without any obvious long-term sequelae , and more recently patients are routinely receiving inferred doses of up to 92 Gy again without measureable toxicity. Furthermore. as both the low (42 Gy) and high (76 Gy) radiation doses used in these animal experiments gave similar results, it may be possible to use even lower doses to produce this same result.
On theoretical grounds. it would seem more appropriate to use adjuvant SIR therapy via the hepatic arterial supply, rather than via the portal vein. While this is true, the realities of surgical practice are that it is technically much easier to cannulate a vein in the portal circulation than the hepatic artery. If adjuvant SIR therapy is to be accepted as a clinical modality, the ease of use by the general surgical community is a major factor to be considered. In addition, it must be ensured that radioactive microspheres do not pass through the liver and enter the pulmonary circulation. Where radioactive microspheres are currently used clinically, a pretreatment procedure involves assessment of lung uptake of activity by analysis of distribution of injected 9Tc-labelled macroaggregated albumin particles of similar size to microspheres. If excessive activity is breaking through the liver to the lung then the treatment is not continued. A similar procedure would need to be employed in the adjuvant setting.
The use of SIR therapy should now be evaluated as an adjuvant treatment for patients at high risk of developing liver metastases.
